Will be interesting to see the fortitude of us long term investors if the FDA comes back tomorrow and says "we need more data" and then says M2M needs a phase 3.

Plausible scenarios that will most likely rock the share price.

One note I did glean from today's presentation is that the preliminary BTD is waiting on getting the blood sample data from the patient trials which of course is slowed by covid. I wasn't sure what we were waiting for. Pretty much the extent of what was said that I didn't already know.